Long-term efficacy of CDK4/6 inhibitors in early HR+, HER2- high-risk breast cancer: An updated systematic review and meta-analysis

QR Code

Long-term efficacy of CDK4/6 inhibitors in early HR+, HER2- high-risk breast cancer: An updated systematic review and meta-analysis

BackgroundThe confirmed efficacy of combining CDK4/6 inhibitors with endocrine therapy (ET) in HR+, HER2− early breast cancer patients in longer follow-up necessitates further investigation. This meta-analysis aims to comprehensively assess the impact of follow-up duration on the therapeutic activit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Liu, Jun Su, Ping Wu, Wenjie Lv
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Pharmacology
Subjects:	CDK4/6 inhibitor early breast cancer meta-analysis follow-up duration iDFS
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1564437/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysis
by: Michele Bottosso, et al.
Published: (2025-10-01)

Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China
by: Caifeng Jia, et al.
Published: (2025-04-01)

Our Experience and Literature Update Regarding Concomitant Radiotherapy with CDK4/6 Inhibitors and Hormonal Therapy in Metastatic Breast Cancer
by: Laura-Florentina Rebegea, et al.
Published: (2025-05-01)

Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors
by: Zehra Sucuoğlu İşleyen, et al.
Published: (2025-07-01)

Optimizing Post-CDK4/6i Strategies In HR +/HER2− Advanced Breast Cancer: A Contemporary Evidence-Based Framework
by: Teena Rajan, et al.

CDK4-6 Inhibitors: Evaluation of Efficacy in Cases of Hormone Receptor-Positive HER2-Negative Breast Cancer with Only Bone Metastasis
by: Serhat SEKMEK, et al.
Published: (2025-04-01)

Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
by: Ioannis A. Voutsadakis
Published: (2025-06-01)

Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspects
by: A. V. Sultanbaev, et al.
Published: (2025-07-01)

Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis
by: Xiaojian Wang, et al.
Published: (2025-07-01)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
by: L. G. Zhukova, et al.
Published: (2020-06-01)

Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
by: Roberta Scafetta, et al.
Published: (2025-08-01)

The ICEDORA study: clinical and demographic characteristics and treatment regimens of patients with HR+ HER2- locally advanced or metastatic breast cancer receiving CDK4/6 inhibitors in real clinical practice
by: I. E. Khatkov, et al.
Published: (2025-07-01)

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey
by: E. V. Artamonova, et al.
Published: (2021-01-01)

Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
by: I. V. Kolyadina
Published: (2021-09-01)

Integrating single-cell regulatory atlas and multi-omics data for differential treatment response and multimodal predictive modeling in CDK 4/6 inhibitor-treated breast cancer
by: Li Yan, et al.
Published: (2025-07-01)

Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 − advanced breast cancer: a meta-analysis
by: Isah Adamu Danbala, et al.
Published: (2025-06-01)

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
by: Emilie Adrian Christiansen, et al.
Published: (2024-12-01)

Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study
by: Yu Zhang, et al.
Published: (2025-07-01)

How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?
by: Peeter Karihtala
Published: (2025-06-01)

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial
by: Jiayu Wang, et al.
Published: (2025-06-01)

A rational approach to dose reduction of CDK4/6 inhibitors in the treatment of patients with advanced breast cancer: A narrative Review
by: I. N. Dyakov, et al.
Published: (2025-07-01)

Long non-coding RNA LINC00473 promotes glioma cells proliferation and invasion by impairing miR-637/CDK6 axis
by: Qiansheng Zhang, et al.
Published: (2019-12-01)

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context
by: Maxwell R. Lloyd, et al.
Published: (2025-08-01)

Circulating Tumor Cells in Early Breast Cancer: A 10-Year Follow-Up Update
by: Tania Rossi, et al.
Published: (2025-05-01)

Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review
by: Chen Z, et al.
Published: (2025-06-01)

Pre-hospital period of acute myocardial infarction in Tomsk City: 15-year follow-up results
by: S. A. Okrugin, et al.
Published: (2004-06-01)

Factors determining the compliance of patients receiving anti-VEGF therapy for macular diseases with long-term follow-up in real-life practice
by: E. V. Bobykin, et al.
Published: (2021-03-01)

Targeting CDK4/6 in Cancer: Molecular Docking and Cytotoxic Evaluation of <i>Thottea siliquosa</i> Root Extract
by: Maruthamuthu Rathinam Elakkiya, et al.
Published: (2025-07-01)

Dynamics of heart rhythm disorders in combatants with acute myocarditis during a 6-month follow-up
by: E.G. Nesukay, et al.
Published: (2024-04-01)

New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy
by: Wei Dai, et al.
Published: (2025-07-01)

Follow-Up of Neuropsychological Development During the First Postnatal Year in Infants with Neonatal Jaundice
by: Tatyana Itova, et al.
Published: (2019-12-01)

APPLICATION OF THE TEXTUAL INFORMATION ANALYSIS METHOD FOR THE PROBLEM OF CLASSIFICATION OF SCIENTIFIC ARTICLE
by: N. O. Ukhanov, et al.
Published: (2022-08-01)

The effects of two combined methods of P53 expression and preoperative serum CEA detection on the prognosis of colorectal cancer
by: Guojun Tong, et al.
Published: (2025-07-01)

Abemaciclib induces G1 arrest and lysosomal dysfunction in canine melanoma cells: synergistic effects with fenbendazole
by: Se-Hoon Kim, et al.
Published: (2025-06-01)

Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers
by: Angela Chan, et al.
Published: (2025-07-01)

A follow-up of gynecological cancer patients: state-of-the-art in Russia
by: S. N. Puzin, et al.
Published: (2014-07-01)

Analysis of the efficiency of a follow-up of patients with dyshormonal breast dysplasia
by: E. A. Sukhareva, et al.
Published: (2014-07-01)

OXYMORTIA IN THE BRUGADA SYNDROME: SUCCESSFUL REANIMATION, ECG-DIAGNOSTICS AND TERTIARY PREVENTION
by: V. V. Savilova, et al.
Published: (2017-12-01)

10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice
by: I. V. Kolyadina
Published: (2021-10-01)

Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2− metastatic breast cancer: clinical and molecular perspectives
by: Jessé Lopes da Silva, et al.
Published: (2025-07-01)